BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38612754)

  • 1. Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) Enhances ATP Production in B Cell Tumors through mTOR and HIF-1α.
    Incrocci R; Monroy Del Toro R; Devitt G; Salimian M; Braich K; Swanson-Mungerson M
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.
    Cen O; Longnecker R
    Mol Cancer Ther; 2011 Apr; 10(4):679-86. PubMed ID: 21282357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer.
    Pang MF; Lin KW; Peh SC
    Cell Mol Biol Lett; 2009; 14(2):222-47. PubMed ID: 19082921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton's tyrosine kinase and STAT3.
    Incrocci R; Barse L; Stone A; Vagvala S; Montesano M; Subramaniam V; Swanson-Mungerson M
    Virology; 2017 Jan; 500():96-102. PubMed ID: 27792904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-κB in B-cell lymphomas to increase MIP-1α production.
    Incrocci R; McAloon J; Montesano M; Bardahl J; Vagvala S; Stone A; Swanson-Mungerson M
    J Med Virol; 2019 May; 91(5):845-855. PubMed ID: 30609049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of Epstein-Barr virus latent membrane protein 2A on the production of B cell activating factor of the tumor necrosis factor family (BAFF), APRIL and their receptors.
    Madayag K; Incrocci R; Swanson-Mungerson M
    Immun Inflamm Dis; 2022 Nov; 10(11):e729. PubMed ID: 36301035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two Pathways of p27
    Sora RP; Ikeda M; Longnecker R
    mBio; 2019 Apr; 10(2):. PubMed ID: 30992353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.
    Cen O; Kannan K; Huck Sappal J; Yu J; Zhang M; Arikan M; Ucur A; Ustek D; Cen Y; Gordon L; Longnecker R
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of HLA-ABC expression through promoter hypermethylation and downmodulation of MIC-A/B surface expression in LMP2A-positive epithelial carcinoma cell lines.
    Singh S; Banerjee S
    Sci Rep; 2020 Mar; 10(1):5415. PubMed ID: 32214110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.
    Vockerodt M; Wei W; Nagy E; Prouzova Z; Schrader A; Kube D; Rowe M; Woodman CB; Murray PG
    J Pathol; 2013 Aug; 230(4):399-409. PubMed ID: 23592216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells.
    Rechsteiner MP; Berger C; Weber M; Sigrist JA; Nadal D; Bernasconi M
    J Gen Virol; 2007 May; 88(Pt 5):1454-1459. PubMed ID: 17412973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells.
    Wowro SJ; Schmitt KRL; Tong G; Berger F; Schubert S
    Int Immunopharmacol; 2016 Jan; 30():9-17. PubMed ID: 26613512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway.
    Swart R; Ruf IK; Sample J; Longnecker R
    J Virol; 2000 Nov; 74(22):10838-45. PubMed ID: 11044134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.
    Ma SD; Tsai MH; Romero-Masters JC; Ranheim EA; Huebner SM; Bristol JA; Delecluse HJ; Kenney SC
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.
    Kraus RJ; Yu X; Cordes BA; Sathiamoorthi S; Iempridee T; Nawandar DM; Ma S; Romero-Masters JC; McChesney KG; Lin Z; Makielski KR; Lee DL; Lambert PF; Johannsen EC; Kenney SC; Mertz JE
    PLoS Pathog; 2017 Jun; 13(6):e1006404. PubMed ID: 28617871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.
    Ikeda M; Hayes CK; Schaller SJ; Longnecker R
    Blood Adv; 2022 Jul; 6(14):4283-4296. PubMed ID: 35605249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of DNA Damage Signaling and Cell Death Responses by Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) and LMP2A in Nasopharyngeal Carcinoma Cells.
    Wasil LR; Wei L; Chang C; Lan L; Shair KH
    J Virol; 2015 Aug; 89(15):7612-24. PubMed ID: 25972552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. K1 and K15 of Kaposi's Sarcoma-Associated Herpesvirus Are Partial Functional Homologues of Latent Membrane Protein 2A of Epstein-Barr Virus.
    Steinbrück L; Gustems M; Medele S; Schulz TF; Lutter D; Hammerschmidt W
    J Virol; 2015 Jul; 89(14):7248-61. PubMed ID: 25948739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus sustains Burkitt's lymphomas and Hodgkin's disease.
    Hammerschmidt W; Sugden B
    Trends Mol Med; 2004 Jul; 10(7):331-6. PubMed ID: 15242681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells.
    Morrison JA; Klingelhutz AJ; Raab-Traub N
    J Virol; 2003 Nov; 77(22):12276-84. PubMed ID: 14581564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.